Ovarian cancer is easy to miss, but don’t let that lead to delays in diagnosis

+Practice

In print

CLINICAL UPDATE

Ovarian cancer is easy to miss, but don’t let that lead to delays in diagnosis

16 February 2022

By Jane Ludemann and Peter Sykes

Wednesday 16 February 2022, 12:40 AM

New Zealand women Lin Klenner, Jane Ludemann and Fazi Bandookwala alongside international women as part of a donated campaign in Piccadilly Circus, London [Image: Supplied]

February is Ovarian Cancer Awareness Month. This article highlights the roles primary care has to play in addressing this serious cancer

Key points, Ovarian cancer is a significant health issue in New Zealand – women have a lower chance of survival at five years than many comparable countries. GP, Pract Green w Pale Yellow

Investigations

References

Ministry of Health. Cancer: Historical Summary 1948–2017. September 2020.

Ministry of Health. Cancer: New registrations and deaths 2013. 2016.

Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068–75.

Hamilton W, Peters TJ, et al. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009;339:b2998.

Gilbert L, Basso O, Sampaslis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012;13(3):285–91.

Pitts MK, Heywood W, et al. High prevalence of symptoms associated with ovarian cancer among Australian women. Aust N Z J Obstet Gynaecol 2011;51(1):71–78.

Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008;113(3):484–89.

BMJ Learning. Recognising early symptoms of ovarian cancer. August 2021. https://new-learning.bmj.com/course/10014285

Sueblinvong T, Carney M. Current understanding of risk factors for ovarian cancer. Curr Treat Options in Oncol 2009;10(1–2):67–81.

Nakamura K, Banno K, et al. Features of ovarian cancer in Lynch syndrome. Mol Clin Oncol 2014;2(6):909–16.

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402–16.

Naumann RW, Hughes BN, Brown J, et al. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. Am J Obstet Gynecol 2021;225(4):397.e1–397.e6.

Rose PW, Rubin G, Perera-Salazar R, et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. BMJ Open 2015;5:e007212.

Dilley J, Allen P, et al. Symptoms reported by women with screen detected invasive epithelial ovarian cancer in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 2015. (unpublished)

Menon U, Gentry-Maharaj A. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397:2182–93.

Funston G, Van Melle M, Baun ML, et al. Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines. BMC Cancer 2019;19(1):1028.

Doroudi M, Kramer B, et al. The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications. Med Screen 2017;24(4):220–22.

Funston G, Hamilton W, et al. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med 2020;17(10):e1003295.

Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193(5):1630–39.

Lehtovirta P, Apter D, Stenman UH. Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol 1990;97(10):930–33.

Arnold M, Rutherford MJ. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019;20(11):1493–505.

Yeoh S, Simcock B, et al. Trends in the overall survival rates in women with advanced ovarian cancer in a single tertiary centre in New Zealand. Aust N Z J Obstet Gynaecol 2019;59:861–66.

Nagle CM, Francis JE, et al. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2011;29(16):2253–58.

Target Ovarian Cancer. Regional Variation in the diagnosis of ovarian cancer in England. 2017. https://targetovariancancer.org.uk

Te Aho o Te Kahu Cancer Control Agency. He Pūrongo Mate Pukupuku o Aotearoa 2020 – The State of Cancer in New Zealand. https://teaho.govt.nz/reports/cancer-state

Health Research Council. https://www.hrc.govt.nz

Firestone RT, Wong KC, Ellison-Loschmann L, et al. Characteristics of ovarian cancer in women residing in Aotearoa, New Zealand: 1993-2004. J Epidemiol Community Health 2009;63(10):814–19.

Gardy J, Dejardin O, Thobie A, et al. Impact of socioeconomic status on survival in patients with ovarian cancer. Int J Gynecol Cancer 2019;29(4):792–801.

ACC. ACC’s Delivery to Priority Populations: Women, Part 1. 22 April 2021.

Target Ovarian Cancer. Pathfinder 2016: Transforming futures for women with ovarian cancer. https://targetovariancancer.org.uk

Spencer RJ, Rice LW, Ye C, et al. Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores. Gynecol Oncol 2019;152(1):106–11.

How to Treat

+How to treat

COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management

Wednesday 26 March 2025, 12:50 AM